AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02998060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D C-Arm (Ziehm Imaging, Nuremberg, Germany)
Description: This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
Study NCT00881855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg Tablets (Sandoz, GmbH)
Study NCT00881855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
Study NCT03370991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: 22 g/day freeze-dried blueberry powder for 12 weeks
Study NCT03370991 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: 22 g/day placebo powder for 12 weeks
Study NCT03625427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
Study NCT03625427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid, 500 mg (Dose 1)
Description: Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
Study NCT03625427 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Palmitoleic acid, 1,000 mg (Dose 2)
Description: Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
Study NCT00426517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath 1H
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
Study NCT00426517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan 5-10 mg/kg total dose given intravenously over 2 days based on patient underlining immune deficiency disorder
Study NCT00426517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Horse Anti-human Thymocyte Globulin (h-ATG)
Description: Conditioning with h-ATG 40 mg/kg total dose over 4 days given intravenously
Study NCT00426517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI 200 - 300 centigray (cGy) in two fractions at day -2 or same day depending on patient underlining immune deficiency disorder
Study NCT00426517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus or equivalent based on response
Description: post Transplantation immunosuppressants
Study NCT00207259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki & Relaxation Response Therapy with Cognitive Restructuring
Description: Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant.
Study NCT04872816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous airway positive pressure
Description: The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
Study NCT04872816 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continuous airway positive pressure
Description: The continuous airway positive pressure will be used as the gold-standard treatment for obstructive sleep apnea for 6 months
Study NCT03430817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citicholine
Description: Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
Study NCT03430817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
Study NCT01317667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RVEc
Study NCT01444781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide
Description: 0.5 mL, Intramuscular each into the right and left deltoid muscle
Study NCT01444781 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide
Description: 0.5 mL, Intramuscular each into the right and left deltoid muscle
Study NCT01444781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
Description: 0.5 mL (each), Intramuscular each into the right and left deltoid muscle
Study NCT01599884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 1800 mg twice daily for 8 weeks
Study NCT01599884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral acetylcysteine
Description: Identical placebo pills twice daily for 8 weeks
Study NCT02254291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
Study NCT02254291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
Study NCT02254291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
Study NCT02210078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes
Description: Given IV
Study NCT02723734 — intervention group
Intervention type: OTHER
Intervention: Decipher® Testing
Description: Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 5 mg of INCB019602 in AM with placebo administration in PM
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 20 mg in AM with placebo administration in PM
Study NCT02104193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin in addition to radiation therapy
Description: simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Study NCT02104193 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Study NCT04038879 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of the heart
Study NCT03772535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomics Testing
Description: The doctor will use genetic test results to prescribe medications that are a most effective for subject.
Study NCT02331758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
Study NCT00691626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Insomnia plus Imagery Rehearsal
Description: patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
Study NCT00691626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT for Insomnia plus psychoeducation
Description: patients receive standard CBT for insomnia combined with psychoeducation
Study NCT04348474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: All patients included in the study will receive HCQ (400 mg BID on D1 and 400 mg/day on D2 to D7) for 7 days.
Study NCT04348474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: All patients included in the study will receive AZT 500 mg per day for 5 days.
Study NCT01291589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Treatment will include elements from effective interventions for reducing risky sexual behaviors
Study NCT02167711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIRT Yttrium-90
Study NCT03716648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DISE-assisted titration
Description: Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
Study NCT03716648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG-guided titration
Description: Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
Study NCT03716648 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subjective titration
Description: Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 5 mg in PM with placebo administration in AM
Study NCT00698789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB019602
Description: 20 mg in PM with placebo administration in AM
Study NCT01617473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant with PBSCs
Description: mobilized PBSCs for 2 consecutive days
Study NCT04078867 — intervention group
Intervention type: PROCEDURE
Intervention: tricuspid valve repair
Description: Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
Study NCT04600440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
Study NCT00253734 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (IM)
Description: 15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
Study NCT00253734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
Study NCT02986035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECA cream
Study NCT02180698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02180698 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02180698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLR4 Agonist GLA-SE
Description: Given intratumorally
Study NCT03661606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated Altitude Chamber
Description: Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study.
Study NCT03609281 — intervention group
Intervention type: RADIATION
Intervention: Ultrasound assessement of uterine scar
Description: 3D ultrasound assessment of scar characteristics
Study NCT03163212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin/FOS
Description: Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
Study NCT00928213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: 40 units daily admission
Study NCT00928213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight Heparin
Description: 40-80 mg/day
Study NCT00928213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No Drug
Description: no treatment
Study NCT03833648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UControl Pain App with Education
Description: The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
Study NCT01116180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin II receptor antagonists (Candesartan)
Description: Seven days of treatment with Candesartan 32 mg, capsules.
Study NCT01116180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule matching the active comparator. Given for 7 days once daily.
Study NCT01121965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling
Description: Pars plana vitrectomy with ILM peeling
Study NCT04566263 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neuroform EZ Stent System
Description: The Stryker Neuroform EZ Stent System is a self-expanding nitinol, compliant, open-cell design that can be deployed by a single operator. The Neuroform EZ Stent System is packaged sterile as a single unit with an introducer sheath and a detachable push wire.
Study NCT02831816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZuraPrep
Description: Apply topically.
Study NCT02831816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep
Description: Apply topically.
Study NCT02831816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZP Vehicle
Description: Apply topically.
Study NCT02513667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
Study NCT02513667 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation
Description: Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
Study NCT00697060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imexon + docetaxel
Description: Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
Study NCT03529994 — intervention group
Intervention type: OTHER
Intervention: Enrollment
Description: All infants enrolled will have work of breathing assessed.
Study NCT00789542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic compression
Description: Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
Study NCT00789542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
Study NCT00789542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine care
Description: Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
Study NCT03524131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: risk-framed leaflet
Description: 2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
Study NCT03524131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: benefits-framed leaflet
Description: 2-sided leaflet, emphasizing benefits of attending an NHS Health Check
Study NCT03524131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: current national leaflet
Description: 4-sided leaflet
Study NCT00352599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Study NCT00352599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Description: Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
Study NCT00352599 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Study NCT01553487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: All cases will be trained by forearm vibration device 5 times a week for six weeks period.
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM atropine
Description: Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV atropine
Description: Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine mixed with second dose succinylcholine
Description: Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM normal saline
Description: 1 ml normal saline IM 30 minutes before induction of anesthesia
Study NCT01761578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ART18Z Bioresorbable stent
Description: The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IM normal saline
Description: 1 ml normal saline IM 30 minutes before induction of anesthesia
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV normal saline
Description: IV 10 ml normal saline 3 minutes before induction of anesthesia
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV normal saline
Description: IV 10 ml normal saline 3 minutes before induction of anesthesia
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline mixed with second dose succinylcholine
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
Study NCT02676011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline mixed with second dose succinylcholine
Description: Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
Study NCT03058757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravesical mitomycin-C 40mg/20ml instillation
Description: neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation~* one day before surgery~* four hours before surgery
Study NCT01827839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine (GSK1437173A)
Description: 2 doses administered intramuscularly in deltoid region of non-dominant arm.
Study NCT05364385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
Description: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
Study NCT02411409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealtheRx
Description: The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
Study NCT03243721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: A high field MRI that will take approximately one hour.